How Should You Time Nebido Testosterone Injections?
Timeline
Video Summary
A 51-year-old man switching testosterone formulations faces a very different dosing strategy with long-acting Nebido. Dr. O’Connor addresses a man outside the United States who is switching from Sustanon 250 to Nebido because he was unhappy with the hormonal ups and downs he experienced on Sustanon. After receiving his first 1,000 mg Nebido injection, the man plans to check testosterone at weeks eight and ten and use those results to determine when to inject again.
Dr. O’Connor explains that Nebido, called Aveed in the United States, is testosterone undecanoate and has a much longer elimination half-life than testosterone cypionate, enanthate, or Sustanon. He emphasizes that the man is overlooking the loading phase. With the regimen discussed, a second 1,000 mg Nebido injection is given six weeks after the first injection before moving toward longer maintenance intervals.
Because testosterone undecanoate has an elimination half-life of about 33 days, Dr. O’Connor explains that reaching steady state takes months. Checking testosterone at eight or ten weeks after only the first injection does not provide the same information as evaluating levels after the loading phase and as the drug approaches steady state. He discusses checking a trough level before a subsequent injection and then individualizing the maintenance interval based on laboratory results, symptoms, and the way the individual metabolizes the drug.
Dr. O’Connor contrasts Nebido with shorter-acting testosterone preparations that can be divided into smaller, more frequent injections. He explains that men who want tighter control over peaks and troughs may find testosterone cypionate, enanthate, or Sustanon easier to adjust than a large, long-acting testosterone undecanoate injection.
The discussion also expands beyond testosterone levels. The 51-year-old man has hypertension and type 2 diabetes treated with Mounjaro, leading Dr. O’Connor to emphasize the ABCDs™ and monitoring blood pressure, A1C, kidney health, red blood cells, prostate health, cardiovascular risk, and other aspects of long-term health while using testosterone.
Finally, Dr. O’Connor discusses injection safety with Nebido. The European formulation discussed contains 1,000 mg of testosterone undecanoate in a 4 mL injection, and he warns about the rare risk of pulmonary oil microembolism and anaphylactic reactions. He stresses that this large-volume, long-acting injection requires appropriate administration and should not be approached like a smaller testosterone injection that can easily be adjusted or microdosed.
Drug Callouts
Condition Callouts
Key Takeaways
- Nebido has very different pharmacokinetics from shorter-acting testosterone esters and should not be managed using the same dosing strategy.
- Dr. O’Connor emphasizes completing the loading phase before trying to interpret testosterone levels and customize long-term Nebido injection timing.
- Testosterone undecanoate has an elimination half-life of about 33 days and can take months to reach steady state.
- Maintenance intervals for long-acting testosterone should consider trough levels, symptoms, pharmacokinetics, and individual differences in metabolism.
- Shorter-acting testosterone preparations can provide greater flexibility for men who prefer smaller doses and tighter control over peaks and troughs.
- Diabetes, hypertension, kidney health, cardiovascular risk, red blood cells, and prostate health remain important when managing long-term testosterone therapy.
- Large-volume testosterone undecanoate injections carry rare but important safety concerns, including pulmonary oil microembolism and anaphylactic reactions.